Search Results
Dec 05, 2025, 09:00 ET NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Six of Neurelis' posters include analyses of data from the completed Stellina study, which was a long-term, Phase 1/2a, open-label pharmacokinetics (PK) and safety study that investigated diazepam nasal spray for the treatment of episodes of frequent seizures in patients with epilepsy aged 2-5 years,
More news about: Neurelis, Inc.
Dec 05, 2025, 05:06 ET Optiml 'Award-Winning Decision Intelligence Platform Secures Major Real Estate Client Wins'
PATRIZIA, a global real assets investment manager, Westbridge Advisory and its subsidiary agradblue, the BEWAG pension fund (PK der BEWAG), Telesto Strategy (US), Longevity Partners (US), and pom+ Consulting have all chosen Optiml as their real estate decision
More news about: OPTIML AG
Dec 04, 2025, 16:30 ET Xenia Hotels & Resorts Provides Business Update
remaining under its share repurchase authorization as of December 4th. Referenced lodging REIT peers include DRH, HST, PK, PEB, and SHO and is based upon publicly available information.Same-Property rooms revenues growth rate of +3.4%, Same-Property non-rooms revenues
More news about: Xenia Hotels & Resorts, Inc.
Dec 04, 2025, 08:55 ET HOLIDAY OF FIRSTS - LIDL US UNVEILS HOLIDAY MEAL DEAL FOR LESS THAN $4 PER PERSON, PLUS LIMITED-EDITION CROISSANT FRAGRANCE
1 pk. Hawaiian sweet rolls5 lbs. jumbo russet potatoes1 pk. French's
More news about: Lidl US
Dec 03, 2025, 14:00 ET Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program
Disease) – Advancing Through GLP and PK Development.HT-ALZ continues to deliver supportive data across absorption, distribution, and neuroinflammatory pathways.Recent highlights:GLP studies underway with positive PK, biodistribution, and CNS-penetration
More news about: Hoth Therapeutics, Inc.
Dec 03, 2025, 08:30 ET Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting
antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctDNA analysis from dose escalation | Swetha Thiruvengadam, MD (City of Hope) | 1:00-1:15 PM EST | Oral presentation
More news about: Foresight Diagnostics, Inc.
Dec 03, 2025, 07:00 ET GRIN Therapeutics to Present on Global Phase 3 Beeline Clinical Trial of Radiprodil at American Epilepsy Society Annual Meeting
(ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II.About GRIN TherapeuticsGRIN Therapeutics, Inc. is dedicated
More news about: GRIN Therapeutics Inc.
Dec 02, 2025, 18:54 ET Accord Healthcare 宣佈推出 Denosumab∇ - 骨骼健康領域第二款生物相似藥
的核准是基於兩項試驗的結果：一項第一期試驗與一項第三期試驗，兩者均達到了主要終點。第一期試驗為一項隨機、雙盲、三組別的藥代動力學 (PK) 研究，於健康成年男性受試者中比較 JUBEREQ 與 Xgeva 的療效。該研究證實，兩種產品的藥代動力學參數具有可比性。4此項第三期研究為一項隨機、雙盲、活性對照、平行組、多中心研究，旨在比較 OSVYRTI 與 Prolia 在絕經後骨質疏鬆症女性患者中的藥代動力學/藥效學 (PK/PD)、療效及安全性。臨床研究結果顯示，OSVYRTI 以及其參照產品 Prolia 高度相似，在藥代動力學、藥效學、安全性及療效方面均無臨床意義上的差異。2.4Accord
More news about: Accord Healthcare
Dec 02, 2025, 18:11 ET Accord Healthcare kündigt Einführung von Denosumab∇ an - zweites Biosimilar im Bereich Knochengesundheit
haben. Die Phase-I-Studie war eine randomisierte, doppelblinde, dreiarmige pharmakokinetische (PK) Studie zum Vergleich von JUBEREQ mit Xgeva bei gesunden erwachsenen Männern. Die Studie zeigte, dass die PK-Parameter zwischen den beiden Produkten vergleichbar waren.4 Die Phase-III-Studie war
More news about: Accord Healthcare
Dec 02, 2025, 17:56 ET Accord Healthcare、骨健康分野で2番目のバイオシミラー「デノスマブ∇」の発売を発表
第III相試験は、閉経後骨粗鬆症の女性を対象に、OSVYRTIとProliaのPK/PD、有効性、安全性を比較した無作為化二重盲検活性対照並行群間多施設共同試験です。臨床試験の結果、OSVYRTIとその参照製品であるProliaは高度に類似しており、PK、PD、安全性、有効性の観点から臨床的に意味のある差異は認められないことが示されました。2、4Accord HealthcareについてAccord Healthcareは、英国および欧州で最も急成長しているジェネリック医薬品およびバイ
More news about: Accord Healthcare
Dec 02, 2025, 17:53 ET Accord Healthcare anuncia o lançamento do Denosumabe∇ - Segundo Biossimilar em Saúde Óssea
atingiram seus desfechos primários. O estudo de Fase I foi um estudo farmacocinético (PK) randomizado, duplo-cego, de três braços, comparando o JUBEREQ com o Xgeva em homens adultos saudáveis. O estudo demonstrou que os parâmetros PK foram comparáveis entre os dois produtos.4 O estudo de Fase III foi
More news about: Accord Healthcare
Dec 02, 2025, 17:50 ET Accord Healthcare anuncia el lanzamiento de Denosumab∇, segundo biosimilar en salud ósea
fase I y un ensayo de fase III que cumplieron con sus criterios de valoración principales. El ensayo de fase I fue un ensayo clínico farmacocinético (PK) aleatorizado, de doble ciego y de tres grupos que comparó JUBEREQ con Xgeva en hombres adultos sanos. El ensayo clínico demostró que los parámetros
More news about: Accord Healthcare
Dec 02, 2025, 16:41 ET Great Hearts Announces New Arizona Campus Opening in Fall 2027
https://enrollaz.greatheartsamerica.org/blossoming-with-gh.About Great HeartsGreat Hearts is a non-profit and the nation's largest provider of classical PK–12 education, serving 30,000+ students across 52 brick and mortar academies in AZ, TX, and LA, and a national online academy. Its classical curriculum
More news about: Great Hearts Arizona
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
objectives include evaluating the regimens' preliminary antitumor activity, assessing ATG-022's immunogenicity, and characterizing its pharmacokinetic (PK) profile.Antengene released updated clinical data from the Phase I/II CLINCH study of ATG-022 monotherapy in patients with advanced GC/GEJC at
More news about: Antengene Corporation Limited
Dec 02, 2025, 02:00 ET Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
pharmacokinetic (PK) study comparing JUBEREQ to Xgeva in healthy adult males. The study demonstrated that PK parameters were found to be comparable between the two products.4 The Phase III study was a randomized, double-blind, active-controlled, parallel arm, multicenter study comparing PK/PD, efficacy
More news about: Accord Healthcare
Dec 02, 2025, 02:00 ET Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health
pharmacokinetic (PK) study comparing JUBEREQ to Xgeva in healthy adult males. The study demonstrated that PK parameters were found to be comparable between the two products.4 The Phase III study was a randomized, double-blind, active-controlled, parallel arm, multicenter study comparing PK/PD, efficacy
More news about: Accord Healthcare
Nov 27, 2025, 06:45 ET In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations
dosing, predict toxicity, simulate rare disease outcomes, and replicate population variability. AI-augmented quantitative systems pharmacology (QSP), PK/PD modeling, and virtual screening are cutting years off development timelines.Medical Device EvaluationMedical device simulation
More news about: DataM Intelligence 4 Market Research LLP
Nov 25, 2025, 08:15 ET Akston Initiates Clinical Trial of Once-Weekly GLP-1 Weight-Management Therapy for Cats
In preclinical studies conducted at Cornell University in laboratory cats, no adverse effects or unanticipated events were observed. Pharmacokinetics (PK) analysis demonstrated that the candidate supports once-weekly dosing. It is built on the company's proprietary Fc-fusion protein platform, which enables
More news about: Akston
Nov 24, 2025, 10:22 ET Ignite Reading Launches National Literacy Movement in Boston
were honored with the Spark Award for their impactful contributions:Dr. Monica McDaniel, Director of Elementary Curriculum PK–5, Meriweather County School District, Greenville, GA.Jennie Bachmeyer, Assistant Superintendent, Red Bluff Elementary School District, Red Bluff,
More news about: Ignite Reading
Nov 24, 2025, 10:00 ET New FAU Lab Schools Campus Officially Celebrates Its New State-of-the-Art Home
one-of-a-kind schooling."Our faculty and staff are the architects of signature student experiences," said Joel Herbst, Ed.D., vice president for PK-12 pre-baccalaureate programs and FAU Lab Schools superintendent. "They make learning sticky by taking students on extraordinary journeys of discovery
More news about: Florida Atlantic University
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
investigators for the study.The Phase 1 part of the trial aims to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.The Phase 2a expansion part of the trial is planned to include three population cohorts: (1) GLIX1 as monotherapy
More news about: BioLineRx Ltd.
Nov 24, 2025, 02:11 ET Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
PIN-5018 as both a monotherapy and in multiple combination regimens. The Phase 1 study employs a dose-escalation design to assess safety, pharmacokinetics (PK), and target engagement/pharmacodynamics (PD). Pin Therapeutics also plans to expand development into additional indications.PIN-5018
More news about: Pin Therapeutics
Nov 21, 2025, 09:05 ET 100 Learning Spaces Transformed, $5 Million Invested: School Specialty and College Football Playoff Foundation Celebrate Impact Across Schools Nationwide
sports organizations, corporations and non-profits to support educators and improve student outcomes. The purpose of the CFP Foundation lies in supporting PK-12 education by elevating the teaching profession. The CFP Foundation inspires and empowers educators by focusing its work in four areas: recognition,
More news about: School Specialty
Nov 20, 2025, 13:16 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
pharmacokinetic (PK) study comparing JUBEREQ to Xgeva in healthy adult males. The study demonstrated that PK parameters were found to be comparable between the two products.4 The Phase III study was a randomized, double-blind, active-controlled, parallel arm, multicenter study comparing PK/PD, efficacy
More news about: Accord BioPharma
Nov 19, 2025, 09:55 ET Promising New Data on Pediatric Use of Pretomanid in Children with Drug-Resistant Tuberculosis Presented at 2025 Union Conference
adult formulation before being evaluated in pediatric populations. IMPAACT 2034 is the first clinical study to evaluate pretomanid pharmacokinetics (PK), safety, and acceptability in children with TB. The Phase 1 IMPAACT 2034 study enrolled 28 female children with RR-TB, including
More news about: IMPAACT